Collaboration with Jazz Pharmaceuticals Accelerates Development of Early-Stage ADC Assets and Strengthens Financial Position $100+ Million Follow-on Financing Provides Two-year Operating Runway Presentations Accepted for ASH Annual Meeting Highlight Potential of Novel IGN Portfolio IMGN632
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Jefferies 2017
CD33-Targeting IMGN779 Demonstrates Favorable Safety Profile and Anti-Leukemia Activity in Ongoing Phase 1 Trial; Dose Escalation Continues with Two Dosing Schedules Preclinical Data Presentations on IMGN779 in Combination and CD123-Targeting IMGN632 Highlight Breadth of ImmunoGen Hematology
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 36 th Annual J.P.
Second ADC Using ImmunoGen’s Novel DNA-Alkylating Payloads to Enter the Clinic WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Stuart A. Arbuckle to its Board of Directors. Mr.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
Significant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018 Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018 Novel ADC Pipeline Continues to Advance with
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 14, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming